Skip to main content

Table 3 Univariate and multivariate analyses of prognostic factors for disease-free survival and overall survival in 184 patients with mid/low rectal cancer

From: Total mesorectal excision with or without preoperative chemoradiotherapy for resectable mid/low rectal cancer: a long-term analysis of a prospective, single-center, randomized trial

Variable

5-year DFS rate

5-year OS rate

Univariate

Multivariate

Univariate

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

Age (> 60 vs. ≤ 60 years)

0.545 (0.249–1.194)

0.129

  

0.862 (0.425–1.748)

0.681

Sex (male vs. female)

0.878 (0.460–1.677)

0.694

  

0.758 (0.397–1.444)

0.399

DAV (≤ 5 cm vs. > 5 cm)

0.698 (0.361–1.315)

0.259

  

0.834 (0.488–1.783)

0.834

pT stage (3–4 vs. 0–2)

2.940 (1.344–6.434)

0.007

2.242 (0.987–5.093)

0.054

2.365 (1.115–5.018)

0.025

pN stage (1–2 vs. 0)

2.903 (1.519–5.546)

0.001

2.281 (1.157–4.495)

0.017

1.801 (0.939–3.453)

0.076

Type of resection (LAR vs. APR)

0.983 (0.485–1.989)

0.961

  

0.693 (0.356–1.348)

0.280

Perioperative chemotherapy cycles (≤ 6 vs. > 6)

2.124 (0.971–4.646)

0.059

  

1.381 (0.682–2.798)

0.370

Treatment (CCRT + TME vs. TME)

1.030 (0.540–1.963)

0.929

  

0.887 (0.461–1.707)

0.720

  1. DFS, disease-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; DAV, distance of the inferior tumor margin from the anal verge; pT stage, pathologic tumor stage; pN stage, pathologic node stage; LAR, low anterior resection; APR, abdominoperineal resection; TME, total mesorectal excision; CCRT, concurrent chemoradiotherapy
  2. Italic values indicate significance of p vaule (p < 0.05)